Endocrinology Search
Endocrinology Endocrinology
infertility
INFERTILITY

Infertility is when a couple of reproductive age is unable to conceive after a year or more of regular unprotected intercourse.

It can be primary if no pregnancy has ever occurred or secondary if pregnancy has occurred irrespective of the outcome.

Ovulation induction is part of the patient's management which aims to achieve development of a single follicle and subsequent ovulation in a woman with anovulation.

Infertility Drug Information

Drug Information

Dosage: Dysmenorrhoea 10 mg bd from day 5-25 of the cycle. Endometriosis 10 mg bd-tds from day 5-25 of the cycle or co

Indication: Locally advanced or metastatic prostate cancer. Genital & extragenital stage I-IV endometriosis. Precociou...

Dosage:  Hormone replacement therapy for women w/ disorders due to natural or surgically induced menopause w/ intact u

Indication: Prevention of premature ovulation in patients undergoing a controlled ovarian stimulation followed by oocyte p...

Indication: Disorders associated w/ progesterone deficiency eg, infertility due to inadequate luteal phase; for use during...

Indication: Premenstrual syndrome (PMS) including premenstrual tension & depression. Luteal phase support as part of a...

Indication: Inhibition of physiological lactation soon after parturition; suppression of established lactation. Hyperprola...

Indication: Anovulation including polycystic ovarian syndrome in women unresponsive to treatment w/ clomifene citrate. Sti...

Indication: Women undergoing superovulation prior to assisted reproductive techniques (ART) & anovulatory or oligo-ovu...

1  /  4
1  /  4
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
DAPA-CKD heralds a new era for dapagliflozin in kidney disease
Pearl Toh, 4 days ago
Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
Empagliflozin reduces CV death, HF hospitalization in HFrEF patients
Roshini Claire Anthony, 3 days ago

In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.